New independent study's findings presented
during Presidential Plenary session at Digestive Disease Week
2024.
MENLO
PARK, Calif., May 20, 2024
/PRNewswire/ -- Phenomix Sciences (Phenomix), a precision medicine
biotechnology company that brings data intelligence to the
treatment of obesity, announces the results of a groundbreaking
independent study led by Mayo Clinic and presented at Digestive
Disease Week 2024 (DDW). The study demonstrates the clinical
utility of the MyPhenome™ Hungry Gut test to predict
response to semaglutide and reduces variability in response to this
weight loss medication. Phenomix co-founder and associate professor
of medicine at Mayo Clinic, Dr. Andres
Acosta, MD, Ph.D. was among a group selected to present
these findings at the Presidential Plenary session at DDW, led by
Dr. Maria Daniela Hurtado Andrade,
M.D., Ph.D. endocrinologist and assistant professor of medicine at
Mayo Clinic, and Sima Fansa, MD,
Mayo Clinic fellow.
The study titled, "Performance of a Machine-Learning Gene Risk
Score Biomarker on Predicting Response to Semaglutide," enrolled 84
participants with obesity (BMI 38.8±6.9 kg/m2)
who were prescribed semaglutide. The patients were tested using the
MyPhenome test and the data analyzed using its
Machine-Learning Gene Risk Score (ML-GRS) to categorize them as
Hungry Gut positive or negative. The Hungry Gut phenotype refers to
patients who have altered postprandial satiety, meaning food passes
through the stomach more rapidly causing them to feel hungry sooner
after a meal.
Weight loss medications such as semaglutide (Ozempic/Wegovy)
result in significant weight loss; however, clinical studies reveal
considerable variability in patient response. The findings of this
study revealed that individuals identified as Hungry Gut positive
achieved 19.5% TBWL at the 12-month mark, while the negative
counterparts experienced only 10% TBWL. This study demonstrated
that MyPhenome test mitigates the variability in outcomes
and identified patients that are more likely to respond better to
semaglutide.
Dr. Hurtado Andrade, PI in the
study said, "Our data support that obesity has a strong genetic and
biological basis that varies within patients living with obesity.
Furthermore, our results underscore the potential of
individualizing therapy to improve outcomes that will ultimately
translate into improved health."
Obesity phenotypes are the combination of genes and other
biometric data that cause obesity, first discovered by Phenomix's
co-founders and Mayo Clinic physicians, Drs. Acosta and
Michael Camilleri, M.D. Using the
MyPhenome test and the company's sophisticated ML
algorithms, providers can more precisely develop treatment plans,
including a diet intervention specific to Hungry Gut and
semaglutide medications.
"We are excited with the results of this independent study of
Phenomix's MyPhenome test at Mayo Clinic," said Mark Bagnall, CEO of Phenomix Sciences. "Demand
for semaglutide marketed as Ozempic and Wegovy, is at an all-time
high; this study showed an ability to identify responders to
semaglutide using our test. We are excited about what lies ahead in
precision medicine for obesity and are hopeful our test will be a
pivotal tool for clinicians across the U.S."
The company recently launched its new three-in-one
MyPhenome obesity phenotyping test, including Hungry
Gut, Hungry Brain, and Emotional Hunger, currently in use by U.S.
providers. For more information, visit
www.phenomixsciences.com.
About Phenomix Sciences
Phenomix Sciences is a
precision obesity biotechnology company on a mission to conquer
obesity globally through the use of our proprietary genetic tests,
unique data sets, and advanced analytics. Phenomix believes that
the key to understanding obesity is its unprecedented access to
clinical and molecular information throughout all stages and
phenotypes of the disease. Phenomix leverages data intelligence for
yielding better accuracy in predicting individual patient response
to specific weight loss interventions and reducing the variability
in weight loss results for patients. For more information, please
visit www.phenomixsciences.com.
View original
content:https://www.prnewswire.com/news-releases/study-demonstrates-myphenome-hungry-gut-test-identifies-responders-to-semaglutide-302149284.html
SOURCE Phenomix Sciences